# Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT

> **NCT03256071** · PHASE2,PHASE3 · UNKNOWN · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 90 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Allogeneic Hematopoietic Stem Cell Transplantation
- Conditioning

## Interventions

- **DRUG:** Decitabine plus Modified BUCY
- **DRUG:** Modified BUCY

## Key facts

- **NCT ID:** NCT03256071
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-09
- **Primary completion:** 2020-09
- **Final completion:** 2021-09
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2017-08-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03256071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03256071, "Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03256071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*